Home
>
US Stocks
>
Achilles Therapeutics Plc - ADR
Achilles Therapeutics Plc - ADR
ACHL

Achilles Therapeutics Plc - ADR (ACHL)

$6.781.35%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open$6.57
Today Low/High$6.46 / $6.79
52 Week Low/High$5.45 / $18.95
Market Cap$273.26M

Company Details

Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.
OrganisationAchilles Therapeutics Plc - ADR
Headquaters245 Hammersmith Road, London, United Kingdom

Discover more

Frequently Asked Questions

What is Achilles Therapeutics Plc - ADR (ACHL) share price today?

Can Indians buy Achilles Therapeutics Plc - ADR (ACHL) shares?

How can I buy Achilles Therapeutics Plc - ADR (ACHL) shares from India?

Can Fractional shares of Achilles Therapeutics Plc - ADR (ACHL) be purchased?

What are the documents required to start investing in Achilles Therapeutics Plc - ADR (ACHL) stocks?

We are a SEBI registered investement advisor